News

OncoGenex Pharma said that this trial is the first of three Phase 3 trials to be initiated under a global collaboration and license agreement between OncoGenex and Teva

The product is based on Labtec’s proprietary LabiPatch platform technology, which is especially suitable for easy, convenient application of patches on the delicate surface of the lip. Labtec

Bionomics’ Phase I study was conducted in healthy male volunteers at the pain and anaesthesia research clinic (PARC) within the Royal Adelaide Hospital and Paul Rolan was the

Takeda, AstraZeneca, Mitsubishi Tanabe, Eisai said that proton pump inhibitor, amoxicillin hydrate, and either clarithromycin or metronidazole is present in this concomitant therapy which is indicated for the

Merck claimed that Staxyn is available in 10 mg orally disintegrating tablets. Staxyn is not interchangeable with vardenafil 10mg filmcoated tablets (Levitra). Staxyn provides higher systemic exposure compared

Simulations Plus said that the preliminary revenues for the pharmaceutical software and services portion of the business were up 17.1% to $2.3m. However, Simulations Plus has also reported

Dyax will retain its rights to subcutaneous DX-88 in other territories, including the US, where DX-88 has been approved by the FDA and is marketed as Kalbitor (ecallantide)

The application for additional approval is based on the result of the Phase III clinical study (ToGA) conducted with patients with HER2-positive advanced or recurrent gastric cancer. ToGA

According to Mylan Pharmaceuticals, the product was determined to be bioequivalent and, therefore, therapeutically equivalent to Pliva’s Hydroxyzine Hydrochloride tablets, a treatment for nervousness and tension.Hydroxyzine hydrochloride sold